These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30064414)

  • 21. Patients on liver transplantation waiting list with Model for End-Stage Liver Disease score ≥ 30: experience in the Organizzazione Centro Sud Trapianti macro area.
    Pretagostini R; Peritore D; Oliveti A; Fiaschetti P; Gabbrielli F; Stabile D; Cenci S; Vaia F
    Transplant Proc; 2013 Sep; 45(7):2610-2. PubMed ID: 24034003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.
    Francoz C; Belghiti J; Castaing D; Chazouillères O; Duclos-Vallée JC; Duvoux C; Lerut J; Le Treut YP; Moreau R; Mandot A; Pageaux G; Samuel D; Thabut D; Valla D; Durand F
    Liver Transpl; 2011 Oct; 17(10):1137-51. PubMed ID: 21695771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver Transplantation in France.
    Durand F; Antoine C; Soubrane O
    Liver Transpl; 2019 May; 25(5):763-770. PubMed ID: 30697904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of liver transplantation waiting list for decompensated cirrhosis in a Spanish tertiary hospital: differences between hepatitis C virus recipients and other etiologies.
    Ibáñez Samaniego L; Pérez Valderas M; Fernández Yunquera A; Rincón Rodríguez D; López Baena JA; Matilla Peña A; Catalina Rodríguez MV; Clemente Ricote G; Bañares Cañizares R; Salcedo Plaza M
    Transplant Proc; 2014 Nov; 46(9):3084-6. PubMed ID: 25420829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.
    Yamashiki N; Sugawara Y; Tamura S; Kaneko J; Nojiri K; Aoki T; Sakamoto Y; Hasegawa K; Koike K; Kokudo N
    Transplant Proc; 2012 Mar; 44(2):389-92. PubMed ID: 22410024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model for End stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores: Ability to predict mortality and removal from liver transplantation waiting list due to poor medical conditions.
    Rahimi-Dehkordi N; Nourijelyani K; Nasiri-Tousi M; Ghodssi-Ghassemabadi R; Azmoudeh-Ardalan F; Nedjat S
    Arch Iran Med; 2014 Feb; 17(2):118-21. PubMed ID: 24527973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL.
    Freitas AC; Shiguihara RS; Monteiro RT; Pazeto TL; Coelho JC
    Arq Bras Cir Dig; 2016 Mar; 29(1):21-5. PubMed ID: 27120734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.
    Wiesner RH; Freeman RB; Mulligan DC
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S261-7. PubMed ID: 15508092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time of Dropout From the Liver Transplant List in Patients With Hepatocellular Carcinoma: Clinical Behavior According to Tumor Characteristics and Severity of Liver Disease.
    Salvalaggio PR; Felga GE; Guardia BD; Almeida MD; Pandullo FL; Matielo CE; Evangelista A; Curvelo L; Rocco RA; Alves JA; Meirelles RF; Filho SP; de Rezende MB; Pedroso PT; Diaz LG; Rusi MB; Viveiros MM; Neves DB
    Transplant Proc; 2016 Sep; 48(7):2319-2322. PubMed ID: 27742288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stratifying Mortality in a Model for End-Stage Liver Disease Waiting List: A Brazilian Single-Center Study.
    Martino RB; Waisberg DR; Dias APM; Inoue VBS; Arantes RM; Haddad LBP; Andraus W; Lopes LD; Galvão FHF; Song ATW; D'Albuquerque LAC
    Transplant Proc; 2018 Apr; 50(3):758-761. PubMed ID: 29661431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.
    Lucey MR; Brown KA; Everson GT; Fung JJ; Gish R; Keeffe EB; Kneteman NM; Lake JR; Martin P; McDiarmid SV; Rakela J; Shiffman ML; So SK; Wiesner RH
    Liver Transpl Surg; 1997 Nov; 3(6):628-37. PubMed ID: 9404965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIGHER VALUES IN LIVER ELASTOGRAPHY AND MELD SCORE ARE MORTALITY PREDICTORS ON LIVER TRANSPLANT WAITING LIST.
    Nacif LS; Paranagua-Vezozzo DC; Matsuda A; Alves VAF; Carrilho FJ; Farias AQ; D'Albuquerque LC; Andraus W
    Arq Bras Cir Dig; 2018 Jun; 31(1):e1360. PubMed ID: 29947694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
    Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.